Lillys IL-23 inhibitor (Mirakizumab) has suffered a minor setback receiving a "complete response letter" from the FDA re
Tweet Content
Lillys IL-23 inhibitor (Mirakizumab) has suffered a minor setback receiving a "complete response letter" from the FDA regarding MIRA application (BLA) for use in ulcerative colitis. The CRL hold up is related to the manufacturing issues (not data/safety) https://t.co/Xs93pFNFAp https://t.co/vlVP8qiqGr
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off